[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100417942":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":52,"collaborators":32,"id":54,"slug":32,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":32,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":32,"enrollmentInfo":62,"targetDuration":32,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":32,"overallStatus":36,"whyStopped":32,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Montefiore Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiotherapy for patients with nonresectable keloids","EXPERIMENTAL","Patients will be seen by a treating radiation oncologist and treatment with the assigned dose schedule will be planned using either EBRT with electrons or high dose-rate radiotherapy (HDR) brachytherapy as deemed appropriate by the treating radiation oncologist. The treatment dose of 25 Gy in 5 fractions will be prescribed to the 90% isodose line.",[13],"Radiation: Radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Radiotherapy","25 Gy in 5 fractions",[9],[21],"Radiation therapy",[23],{"name":24,"affiliation":25,"role":26},"Keyur J Mehta, MD","Montefiore","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Daniel Alicea","CONTACT","646-538-9909",null,"daniel.alicea2@einsteinmed.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","The Bronx","New York","10467","United States",{"type":42,"coordinates":43},"Point",[44,45],-73.86641,40.84985,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":50,"phoneExt":32,"email":51},"Keyur Mehta, MD","718-920-5636","joklein@montefiore.org",{"type":53,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100417942",false,"NCT04722263","Radiotherapy for Keloids","Primary Radiotherapy for the Treatment of Keloids: A Pilot Study","Inclusion Criteria:\n\n* Clinically diagnosed keloid\n* Surgical excision of keloid is either contraindicated or patient has declined treatment with surgical excision (Note: patients with keloids that recurred after previous resection are eligible, as long as the current keloid is either unresectable or patient has declined resection)\n* Age ≥ 18\n* Study specific informed consent provided\n\nExclusion Criteria:\n\n* Prior RT to the area of interest that would result in overlap of radiation therapy fields\n* Females of child bearing age without a negative serum pregnancy test prior to initiation of RT or unwilling to use contraception prior to and during the radiation course\n* Keloids in areas where radiation therapy introduces unacceptable high risk of toxicity as determined by the treating radiation oncologist\n* Uncontrolled intercurrent illness (e.g. symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, or psychiatric situation) that would limit compliance with study requirements as judged by the treatment physicians","ALL","18 Years",{"count":63,"type":64},15,"ESTIMATED","INTERVENTIONAL",[67],"NA","The purpose of this pilot study is to evaluate the safety and efficacy of radiation therapy (RT) in the treatment of unresected keloids.",[70],"Keloid","2026-01-27",{"date":73,"type":74},"2026-01-30","ACTUAL",{"date":76,"type":74},"2020-12-01",{"date":78,"type":64},"2026-06",{"name":5,"class":6},1]